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Abstract: Background In the first year following renal transplantation, preventing weight gain to minimize
overweight or obesity is particularly important. The aim of this study is to test the effect of an 8-month
behavioral intervention BMI and physical activity. Methods This randomized controlled study included
123 adult kidney or kidney-pancreas recipients. Patients were randomized to usual (1 educational session,
then weight self-monitoring) and intervention care (usual care plus 7-8 counseling sessions). Alongside
weight, body composition, and physical activity, satisfaction and perceptions regarding care were mea-
sured at weeks 2-6 (baseline), then at months 8 and 12. Results Both groups reported comparably high
satisfaction. The intervention group (IG) reported more chronic care-related activities. In patients with
BMIs ฀ 18.5, mean weight gain (from baseline) was unexpectedly low in both groups: at month 8, +0.04
kg/m2 in IG patients and +0.14 kg/m2 in the control group (P = 0.590), and respectively, +0.03 kg/m2
and +0.19 kg/m2 at month 12 (P = 0.454). Both groups were physically active, walking averages of 10
807 (IG) and 11 093 (control group) steps per day at month 8 (P = 0.823), and respectively 9773 and
11 217 at month 12 (P = 0.195). Conclusions The behavioral intervention had high patient acceptance
and supported patients in maintaining their weight, but had no superior effect on a single educational
session. Further research is needed to assess patient weight gain risk profiles to stratify the intervention.
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Comparison of a Behavioral Versus an 
Educational Weight Management Intervention 
After Renal Transplantation: A Randomized 
Controlled Trial
Gabriela Schmid-Mohler, PhD, RN,1,2 Patrizia Zala, MScN, RN,2 Nicole Graf, PhD,3  
Patrick Witschi, RN,2 Thomas F. Mueller, MD,2 Rudolf Peter Wüthrich, MD,2 Laura Huber, MSc,1  
Thomas Fehr, MD,2,4 and Rebecca Spirig, PhD, RN5
I
n spite of its many benefits, kidney transplantation is also 
linked to a range of comorbidities, including cardiovascu-
lar disease and diabetes,1 that are exacerbated by overweight 
(BMI 25.00–29.99) or obesity (BMI ≥30). Unfortunately, many 
kidney failure patients have trouble managing their weight. 
Even in the first year following renal transplantation, weight 
gain is common: internationally, mean country-level increases 
range from 1.92 to 5.7 kg.3,4 A survey in a large Swiss cohort 
showed that the percentage of recipients with normal weight 
decreased from 42.9% to 39.6% within the first 3 years 
Kidney Transplantation
Background. In the first year following renal transplantation, preventing weight gain to minimize overweight or obesity 
is particularly important. The aim of this study is to test the effect of an 8-month behavioral intervention BMI and physical 
activity. Methods. This randomized controlled study included 123 adult kidney or kidney-pancreas recipients. Patients 
were randomized to usual (1 educational session, then weight self-monitoring) and intervention care (usual care plus 7–8 
counseling sessions). Alongside weight, body composition, and physical activity, satisfaction and perceptions regarding 
care were measured at weeks 2–6 (baseline), then at months 8 and 12. Results. Both groups reported comparably high 
satisfaction. The intervention group (IG) reported more chronic care-related activities. In patients with BMIs ≥ 18.5, mean 
weight gain (from baseline) was unexpectedly low in both groups: at month 8, +0.04 kg/m2 in IG patients and +0.14 kg/m2 
in the control group (P = 0.590), and respectively, +0.03 kg/m2 and +0.19 kg/m2 at month 12 (P = 0.454). Both groups 
were physically active, walking averages of 10 807 (IG) and 11 093 (control group) steps per day at month 8 (P = 0.823), 
and respectively 9773 and 11 217 at month 12 (P = 0.195). Conclusions. The behavioral intervention had high patient 
acceptance and supported patients in maintaining their weight, but had no superior effect on a single educational session. 
Further research is needed to assess patient weight gain risk profiles to stratify the intervention.
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posttransplantation, whereas the prevalence of overweight 
(BMI ≥25) increased from 34.6% to 37.3% and of obesity from 
19.3% to 20.9%2—double that of the normal Swiss popula-
tion.5 As patients with normal weight commonly shift to over-
weight and obesity over a 3-year period, prevention of weight 
gain is relevant to all patients regardless of their baseline BMI.
Compared with normal weight (BMI 18.5–24.9)6-8 or oth-
erwise nonobese renal transplant recipients (BMI <30),9 recent 
findings indicate that obese renal transplant recipients have 
increased mortality rates6,7 due to cardiovascular disease,9 
delayed graft function,7-9 acute rejection,7 and allograft loss.7,8 
While reports disagree on the consistency of correlations 
between obesity and mortality8,9 or acute rejection,9 weight 
gain—particularly if it is rapid—in the first year posttransplant 
remains strongly associated with poor clinical outcomes—
regardless of baseline BMI. For example, rapid first-year weight 
gain of 20% correlates with an increased risk of death,10 rapid 
increases in BMI correlate with higher risks of new onset diabe-
tes,11 and a BMI increase above 5% correlates with graft loss.12 
Therefore, establishing a healthy diet and routine physical 
activity is especially important in the immediate posttransplant 
period. This is the case for patients with normal weight as well 
as for patients with overweight or obesity.
Despite the relevance of weight gain and physical activity on 
posttransplant outcomes, the implementation of weight man-
agement interventions in posttransplant care varies widely in 
regard to dose (none, single versus various), length (once ver-
sus y posttransplant), content (topics), and method (educational 
versus behavioral).13,14 Current guidelines recommend struc-
tured programs for patients with obesity and not further defined 
encouragement of healthy lifestyle in all patients.15 While single 
educational sessions are well received in practice, the implemen-
tation of complex lifestyle interventions in clinical practice faces 
various barriers, of which lack of resources, lack of feasibility, or 
low uptake by patients represent only a few.13 Given this situa-
tion, our aim was to provide weight management support after 
kidney transplantation while the intervention must have high 
practicability and patient acceptability. Contextual prerequisites 
were that the bundle of interventions must contribute to the con-
tinuity of care and not lead to further fragmentation of care, while 
integrating a holistic care approach that balances each patient's 
medical and behavioral issues with his or her psychosocial needs 
and concerns. To ensure the relevance of the program for this 
patient group, kidney recipients were asked both to help define 
the program's topics and to review the educational material.
Objective
This study's objective was to assess the efficacy of a newly 
developed behavioral 8-month intervention (versus 1 educa-
tional session within the first mo) postrenal transplantation, 
based on 2 outcomes. The primary outcome was BMI change, 
as measured in patients with baseline BMIs of ≥18.5 (normal 
weight or above). Our secondary outcomes were BMI change 
in patients with BMIs of <18.5 (underweight), and change in 
physical activity across the entire sample.
MATERIALS AND METHODS
Design
A single-center randomized controlled study was under-
taken in the University Hospital Zurich's Division of 
Nephrology. Data collection started in May 2012 and finished 
in February 2018. A total of 123 patients were included. 
Ethical approval was granted by the Ethics Committee of 
Canton of Zurich, Switzerland (KEK ZH-Nr. 2011-0411).
Eligibility Criteria
Inclusion criteria were adult age (≥18) and having received 
a kidney or kidney-pancreas transplantation in the past 6 
weeks. Exclusion criteria were (1) inability to speak or read 
German or Italian; or (2) previous or combined lung, liver or 
heart transplantation.
Data Collection
Patients who fulfilled the eligibility criteria were approached 
by Advanced Practice Nurse (APN) and informed about the 
study. If they provided written informed consent, baseline data 
were collected (first measurement). Then, patients were ran-
domly allocated 1:1 to the usual care (CG) or intervention group 
(IG). For this purpose, randomization envelopes prepared and 
sealed by the Cantonal Pharmacy of Zurich using a block rand-
omization of 10 were opened by the APN in front of the patient.
The second measurement took place at month 8 or 9 after 
completion of the intervention, with a third measurement at 
month 12 (Figure 1). The intervention was not blinded to the 
patient; however, the Nephrology team was not informed 
about group affiliations.
Patients who were approached but declined to participate 
were asked for written informed consent to allow retrieval of 
their data from their electronic patient charts.
Usual Care and Intervention
Educational Intervention (CG)
The APN, a master-prepared nurse delivered all patients 
the same 45- to 60-minute educational intervention. Its con-
tent was based on a previously developed brochure16,17 and 
tailored to each patient's individual situation, which was 
explored via a standardized assessment (Intervention 1). Apart 
from medication self-management, emotional and psycho-
social concerns were addressed. The 76-page-long brochure 
covers topics perceived as relevant by healthcare professionals 
and/or patients and is based on 3 evidence-based guidelines: 
the European Best Practice Guidelines, the Kidney Disease 
Improving Global Outcome, and United Kingdom National 
Institute of Health and Care Excellence projects. The qual-
ity of the guidelines had been evaluated by the first author 
according to the AGREE criteria and found to be good or 
excellent.18 The relevance of weight management, physical 
activity, and recommendations regarding diet and activity are 
addressed in detail in the brochure. The content of the bro-
chure was extensively reviewed by clinical experts for correct-
ness and by patients for relevance to the topics for their daily 
life. As standard postrenal transplantation care, patients were 
instructed and trained to self-monitor and record their body 
weight, blood pressure, and pulse daily in a Leporello booklet.
Behavioral Intervention (IG)
In addition to usual care, the IG received additional interven-
tions (interventions 2–8 or 9) focusing on their behavior regarding 
maintenance/achievement of a normal body weight and the inte-
gration of physical activity into a daily routine. Patients included 
2–4 weeks posttransplant received a total of 9 interventions, while 
those included 4–6 weeks posttransplant received 8. Interventions 
2 and 3 lasted 45–60 minutes and generally took place at the 
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hospital. Interventions 4–9 lasted 15–30 minutes and were con-
ducted by telephone or face to face at the hospital—according 
to patients' preferences. Counseling followed motivational inter-
viewing technique guidelines.19,20 Further intervention details are 
described in Table S1 (SDC, http://links.lww.com/TXD/A227) 
and Figure S1 (SDC, http://links.lww.com/TXD/A227).
Outcomes
Primary endpoint:
• Difference in BMI between baseline and month 8 (only 
in patients with BMIs≥18.5)
Secondary endpoints:
Differences in
• BMI between baseline and month 8 (in patients with 
BMIs <18.5)
• BMI between baseline and month 12 (in patients with 
BMIs ≥18.5 and <18.5)
• lean tissue mass (LTM) between baseline and month 8 
and 12, and between groups at months 8 and 12
• waist-hip ratio between baseline and month 8 and 12, 
and between groups at months 8 and 12
• self-reported physical activity at months 8 and 12 
(between groups)
• number of steps (total and medium to high activity, 
via “StepWatch 3” accelerometer) at months 8 and 12 
(between groups)
Variables
Body Weight/Height Ratio (kg/m2)
Body mass and height were measured via a SECA sugges-
tion: SECA measuring station and BMI calculated. If necessary, 
weight was measured in another hospital or at home. With the 
consent from nonparticipants (NPs), data were extracted from 
their electronic patient charts. BMI categories matched those 
of the WHO.21
Body Composition
LTM (% of body weight) and lean tissue index (LTI) (LTM 
in kg/[height in m]2) were assessed with body impedance 
analysis (Fresenius suggestion: Fresenius). Waist-to-hip ratio 
was calculated as circumference of the waist divided by the 
circumference of the hip.
Physical Activity
The self-report instrument asked for the amount of physical 
activity (intensive, moderate, walking) over the last 7 days.22 
For this study, each patient's overall IPAQ score was calcu-
lated in MET (metabolic equivalent of task) minutes per week. 
The total score was reported to moderately correlate with 
accelerometer data in previous research (r  = 0.30), which is 
comparable to other self-report instruments assessing physical 
activity.23,24 Physical activity was further assessed in months 8 
and 12 via the StepWatch 3 suggestion: Stepwatch 3 acceler-
ometer, which differentiates between 3 activity levels: low (1–
30 steps/min), medium (31–80 steps/min), and high (≥80 steps/
min). Patients were instructed to wear the accelerometer on 
their ankle for 7 days. Cardiovascular minutes were calculated 
as the sum of minutes per 7 days that the patient's average step 
rate was ≥100 per minute for ≥10 minutes.25
Perception of Care
The 26-item Patient Assessment of Chronic Illness Care 
(PACIC) questionnaire assesses chronic care activities based 
on the Chronic Care Model.26 It allows 2 scoring options. The 
first measures patient activation, delivery system, goal setting, 
problem solving, and follow-up care options and their qual-
ity27; the second measures how often and how well respondents 
felt care staff advised, reached agreement with, assisted and 
arranged resources for them.28 The instrument showed good 
internal consistency (Cronbach's alpha ≥0.78) for all subscales 
and satisfactory convergent validity with the European Project 
on Patient Evaluation of General Practice Care.29 Possible 
scores range from 1 (lowest quality) to 5 (highest quality).
Patient satisfaction with counseling was measured via 11 
items rated on a 4-point Likert scale—(1) applies fully, (2) applies 
mostly, (3) applies partly, and (4) does not apply at all. An explor-
atory principal component analysis using Varimax Rotation 
identified 4 dimensions. Of the 11 items, 9 loaded on single com-
ponents: 2 on “tailored to my situation,” 3 on “fostering behavior 
change,” 2 on “quality of material,” and 2 on “intended use in 
future.” The remaining 2 were excluded because they loaded on 
multiple factors, revealing a lack of conceptual clarity. Therefore, 
the final questionnaire contained 9 items. It was assessed once for 
each group, at month 1 for the CG and at month 8 for the IG.
Analysis
Sample Size
Analysis of data from a 20-patient pilot study indicated that 
2 samples of 64 patients each would achieve 80% power to 
detect a 1.0 kg/m2 difference between the null hypothesis (that 
both groups' mean change would be 0.0 kg/m2) and the alter-
native hypothesis (that the mean intervention effect would be 
≥1.0 kg/m2), with estimated group standard deviations of 2.0 
FIGURE 1. Timeline of measurements, randomization, and interventions.
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and 2.0, and with a significance level (alpha) of 0.05 using a 
2-sided 2-sample t-test. In the sample size calculation for the 
primary endpoint, patients with BMI < 18.5 (n = 2) and outli-
ers (n = 1) were excluded, resulting in a sample size of 17 for 
the sample size calculation.
Quantitative Data
The primary endpoint, that is, BMI difference between base-
line and month 8, was analyzed with a Mann-Whitney U test. A 
sensitivity analysis was also performed. Log-transformed month 
8 IG and CG BMIs were compared via a linear model, while 
controlling for baseline BMI, depression, and prednisone dose. 
Secondary endpoints were analyzed via a Mann-Whitney U test 
(for continuous variables) and either a chi-square test or a Fisher 
exact test (for categorical variables) as appropriate. Treatment 
groups were tested using a 2-sided significance level of 0.05.
RESULTS
Study Participants
Of the 212 patients who were invited to participate, 123 
(58%) were enrolled. Via randomization, 61 were assigned to 
the IG and 62 to the CG (Figure 2). Of the 89 who declined 
participation, 87 provided written informed consent for data 
retrieval from their electronic charts.
Demographic and baseline variables for the overall group 
(stratified by treatment group) are shown in Table  1. The 
IG and the CG differed in regard to creatinine (P  = 0.011) 
and eGFR (P = 0.018); all other characteristics were equally 
distributed.
Treatment Compliance
In the IG, 88.5% of patients participated in ≥7 counseling 
interviews. While most (86.9%) had ≥4 counseling interviews 
at the hospital, over half (57.4%) also had ≥3 by telephone. 
The mean interview duration was 35 minutes for the IG and 
64 minutes for the CG. In the CG, 57 (91.9%) patients had 1 
counseling session, 5 (8.1%) requested a second one to ensure 
safe self-management.
Perception of Care
PACIC: Chronic Care Model-Related Activities
Based on data from 10 PACIC questionnaire subscales and 
2 summaries, a Mann-Whitney U test was used to compare 
FIGURE 2. Study flow chart.
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IG and CG patients' perceptions of the care they had received 
(Table 2). The differences were statistically significant for all 
scores except “patient activation.”
Satisfaction With Counseling
A Mann-Whitney U test was used to compare the data 
from the 2 groups, regarding Satisfaction with Counseling 
Questionnaire subscales and 1 summary score (Table 3). No 
statistically significant differences were found.
Changes in BMI at Months 8 and 12
Month 8
In patients with BMIs ≥18.5, the mean change from baseline 
BMI to month 8 was 0.039 (95% CI, −0.440 to 0.519) for the 
IG and 0.143 (95% CI, −0.369 to 0.656) for the CG (Table 4 
and Figure 3). A Mann-Whitney U test indicated that this differ-
ence was nonsignificant (P = 0.590). Five patients in the IG and 
4 in the CG had baseline BMIs <18.5 (underweight). The mean 
BMI change from baseline to month 8 in those patients was 
1.588 (95% CI, −1.002 to 4.177) for the IG and 2.015 (95% 
CI, −0.474 to 4.505) for the CG. The exact Mann-Whitney U 
test indicated that this difference was nonsignificant (P = 0.730).
Month 12
A Mann-Whitney U test was used to compare baseline to 
month 12 changes between the treatment groups. No statisti-
cally significant differences were found for patients with BMIs 
≥ 18.5 (P = 0.454) and BMIs < 18.5 (P = 0.730).
As illustrated in Figure 3, while the IG's overall weight gain 
was lower than for the CG, stratification reveals varying pat-
terns of weight loss and gain in both groups (nonsignificant). 
In patients with obesity (BMI ≥ 30), only IG members (n = 7, 
versus 11 in the CG) showed ongoing weight loss after both 
8 and 12 months.
Body Composition
Changes in both treatment groups' LTI from baseline to 
month 8 and month 12 were compared via a Mann-Whitney 
U test. No statistically significant differences were detected at 
month 8 (all P = 0.985, female P = 0.409, male P = 0.564) or 
month 12 (all P = 0.413, female P = 0.289, male P = 0.795); nor 
were any significant differences detected between the groups 
at month 8 (all P = 0.472, female P = 0.481, male P = 0.124) 
or 12 (female and male P = 0.616, female P = 0.371, P = male 
0.279) (Figure 4). Waist-to-hip ratio decreased slightly in both 
groups over the entire 12 months (Figure 5); however, no sig-
nificant difference between the groups was detected.
Physical Activity at Month 8 and 12
Accelerometer
The average daily numbers of steps and of steps with 
medium to high activity cadence of the 2 treatment groups at 
months 8 and 12 were compared via a Mann-Whitney U test. 
Both groups walked between 9773 and 11 217 steps per day, 
of which between 6870 and 8260 were of moderate or high 
intensity (Figure  6). No statistically significant differences 
TABLE 1.
Demographic and clinical characteristics of all randomized patients (N = 123) at baseline and patients who declined 
participation (N = 87)
Overall IG CG NP
N 123 61 62 87
Age, mean (SD) 50.2 (13.1) 50.5 (13.8) 49.8 (12.6) 51.0 (15.4)
Kidney transplantation (%) 120 (97.6) 60 (98.4) 60 (96.8) 82 (94.3)
Kidney-pancreas transplantation (%) 3 (2.4) 1 (1.6) 2 (3.2) 5 (5.7)
First transplantation (%) 98 (79.7) 53 (86.9) 45 (72.6) 69 (79.3)
Gender = male (%) 76 (61.8) 37 (60.7) 39 (62.9) 56 (64.4)
Creatinine at baseline, mean (SD) 141.8 (50.5) 132.9 (46.2) 150.6 (53.3) 144.8 (52.9)
eGFR at baseline, mean (SD) 49.9 (15.9) 52.8 (15.4) 47.0 (15.9) 48.8 (18.0)
Urea at baseline, mean (SD) 10.2 (4.2) 10.0 (5.0) 10.3 (3.4) 10.7 (4.1)
Hemoglobin at baseline, mean (SD) 107.7 (17.1) 109.6 (17.0) 105.8 (17.0) 103.9 (15.9)
Hypertension = yes (%) 54 (43.9) 28 (45.9) 26 (41.9) 44 (51.2)
Diabetes at time of transplantation (%) 14 (11.4) 6 (9.8) 8 (12.9) 17 (19.5)
Smoking at baseline = yes (%) 14 (11.4) 10 (16.4) 4 (6.5) Not assessed
Prednison, mg/day     
 Baseline, mean (SD) 20.1 (8.9) 20.6 (8.3) 19.6 (9.5) 20.4 (8.6)
 Mo 8, mean (SD) 5.3 (13.5) 6.4 (18.8) 4.3 (3.9) 4.6 (3.1)
 Mo 12, mean (SD) 3.0 (3.7) 2.9 (3.5) 3.2 (3.9) 3.5 (3.6)
Etiology (%)     
 Diabetes Type 1 or 2 7 (5.7) 3 (4.9) 4 (6.5) 10 (11.4)
 Hypertensive kidney disease 9 (7.3) 3 (4.9) 6 (9.7) 4 (4.6)
 Glomerulonephritis 43 (35.0) 18 (29.5) 25 (40.3) 34 (39.1)
 Polycystic kidney disease 28 (22.8) 20 (32.8) 8 (12.9) 14 (16.1)
 Congenital genetic kidney disease 12 (9.8) 7 (11.5) 5 (8.1) 6 (6.9)
 Genetic (others than polycystic) 7 (5.7) 2 (3.3) 5 (8.1) 1 (1.1)
 Unknown 15 (12.2) 7 (11.5) 8 (12.9) 11 (12.6)
 Others 2 (1.6) 1 (1.6) 1 (1.6) 7 (8.0)
CG, control group; IG, intervention group; NP, nonparticipant; SD, standard deviation.
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TABLE 2.
PACIC at month 8, stratified by treatment group
Description of the score [27, 28] IG CG P
N  61 62 NA
PACIC sum, mean (SD)  3.8 (0.6) 3.2 (0.8) 0.000
PACIC activation, mean (SD) Actions that solicit patient input and involvement in decision-making 4.0 (0.8) 3.7 (1.1) 0.577
PACIC delivery, mean (SD) Actions that organize care and provide information to patients to enhance their understanding of care 4.5 (0.6) 4.1 (0.8) 0.007
PACIC goal, mean (SD) Acquiring information for and setting of specific, collaborative goals 3.6 (0.8) 2.7 (1.0) 0.000
PACIC problem, mean (SD) Considering potential barriers and the patient's social and cultural environment in making treatment 
plans
4.0 (0.8) 3.3 (1.2) 0.002
PACIC follow-up, mean (SD) Arranging care that extends and reinforces office-based treatment, and making proactive contact with 
patients to assess progress and coordinate care
3.1 (1.0) 2.6 (1.1) 0.032
AS sum, mean (SD)  3.9 (0.6) 3.3 (0.9) 0.000
AS assessment, mean (SD) Ask about/assess behavioral health risk(s) and factors affecting choice of behavior change goals/
methods
4.0 (0.8) 3.5 (0.9) 0.010
AS advice, mean (SD) Give clear, specific, and personalized behavior change advice, including information about personal 
health harms and benefits
3.7 (0.7) 3.1 (0.9) 0.000
AS agreement, mean (SD) Collaboratively select appropriate treatment goals and methods based on the patient's interest in and 
willingness to change the behavior
4.1 (0.8) 3.2 (1.0) 0.000
AS assistance, mean (SD) Using behavior change techniques (self-help and/or counseling), aid the patient in achieving agreed-
upon goals by acquiring the skills, confidence, and social/environmental supports for behavior 
change, supplemented with adjunctive medical treatments when appropriate
3.5 (0.8) 2.8 (1.1) 0.002
AS arrangement, mean (SD) Schedule follow-up contacts (in person or by telephone) to provide ongoing assistance/support and to 
adjust the treatment plan as needed, including referral to more intensive or specialized treatment
3.1 (1.0) 2.6 (1.1) 0.025
CG, control group; IG, intervention group; PACIC, Patient Assessment of Chronic Illness Care; SD, standard deviation.
TABLE 3.
Satisfaction with counseling at month 1 for CG and at month 8 for IG, stratified by treatment group
IG CG P
Tailored to my situation (N) 53 51  
Tailored to my situation, mean (SD) 1.30 (0.44) 1.48 (0.51) 0.088
Fostering behavior change (N) 54 38  
Fostering behavior change, mean (SD) 1.48 (0.49) 1.65 (0.53) 0.089
Quality of material (N) 54 49  
Quality of material, mean (SD) 1.30 (0.46) 1.18 (0.43) 0.095
Intended use in future (N) 53 48  
Intended use in future, mean (SD) 1.23 (0.49) 1.23 (0.41) 0.601
Sum score (N) 50 30  
Sum score, mean (SD) 1.33 1.37 0.261
CG, control group; IG, intervention group; SD, standard deviation.
TABLE 4.







Mo 12  
IG CG IG CG IG CG NP
BMI <18.5 (N) 5 4 2 5 4 2 5 4 2
BMI <18.5, mean (SD) 17.77 (0.43) 17.69 (0.48) 17.63 (0.27) 19.36 (1.88) 19.71 (2.03) 17.83 (0.21) 19.60 (1.66) 19.97 (2.66) 18.59 (1.10)
BMI ≥18.5 (N) 56 58 84 56 58 79 56 58 79
BMI ≥18.5, mean (SD) 25.06 (3.61) 26.01 (4.66) 25.38 (4.03) 25.10 (3.39) 26.15 (4.37) 25.77 (4.11) 25.09 (3.49) 26.20 (4.37) 25.68 (4.09)
Further stratified          
 18.5 ≤ BMI <25 (N) 27 25 39 27 25 38 27 25 37
 18.5 ≤ BMI <25, mean (SD) 22.09 (1.71) 21.76 (1.94) 21.78 (1.76) 22.77 (1.82) 22.60 (2.29) 22.84 (2.82) 22.73 (2.23) 22.71 (2.48) 22.87 (2.58)
 25 ≤ BMI <30 (N) 22 22 36 22 22 34 22 22 34
 25 ≤ BMI <30, mean (SD) 26.58 (1.10) 27.19 (1.59) 27.48 (1.49) 26.08 (2.10) 27.14 (2.08) 27.66 (2.40) 26.18 (2.05) 27.01 (1.96) 27.13 (2.83)
 BMI ≥30 (N) 7 11 9 7 11 7 7 11 8
 BMI ≥30, mean (SD) 31.75 (1.45) 33.29 (1.74) 32.58 (1.74) 31.00 (2.67) 32.24 (3.53) 32.52 (3.33) 30.75 (2.89) 32.49 (3.27) 32.52 (3.08)
CG, control group; IG, intervention group; NP, nonparticipant; SD, standard deviation.
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were found either for average daily number of steps (mo 8 
P = 0.823; mo 12 P = 0.195) or for average daily number of 
steps with medium to high activity cadence (mo 8 P = 0.748; 
mo 12 P  =  0.163). Similarly, numbers of cardiovascular 
minutes did not differ significantly (mo 8 P = 0.586; mo 12 
P = 0.851).
IPAQ Scores
A Mann-Whitney U test comparing intervention and CG 
IPAQ scores for walking, moderate, vigorous, and sum of 
FIGURE 3. BMI at baseline, month 8 and 12, stratified by treatment group and baseline BMI. Error bars show mean and 95% confidence 
interval. Number of patients.
FIGURE 4. LTI at baseline, month 8 and 12, stratified by treatment 
group and gender. Error bars show mean and 95% confidence 
interval. LTI, lean tissue index.
FIGURE 5. Waist-to-hip ratio at baseline, month 8 and 12, stratified 
by treatment group and gender. Error bars show mean and 95% 
confidence interval.
FIGURE 6. Number of steps at month 8 and 12, stratified by 
intensity. Error bars show mean and 95% confidence interval.
FIGURE 7. IPAQ METs at baseline, month 8 and 12, stratified by 
intensity. Error bars show mean and 95% confidence interval. MET, 
metabolic equivalent of task.
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moderate and vigorous exercise at months 8 and 12 indicated 
no significant differences (walking [mo 8 P = 0.156, mo 12 
P = 0.211], moderate [mo 8 P = 0.191, mo 12 P = 0.223], 
vigorous [mo 8 P = 0.141, mo 12 P = 0.603], sum of moderate 
and vigorous [mo 8 P = 0.797, mo 12 P = 0.363] or the sum 
score [mo 8 P = 0.760, mo 12 P = 0.248]) (Figure 7).
DISCUSSION
This RCT's aim was to evaluate the effect of an 8-month 
behavioral intervention on weight and physical activity to 
provide guidance for evidence-based posttransplant care. As 
intended, while both groups were highly satisfied with the 
intervention module they shared, the IG received consider-
ably more chronic-care related training from their nephrology 
team than the CG.
Both IG and CG patients showed good weight management 
over the full 12 month measurement period: those with BMIs 
<18.5 were able to increase their body weight to the normal 
range in both groups; those with BMIs ≥18.5 were able to 
maintain their mean BMI in the IG (+0.03 kg/m2); the CG had 
only a minimal mean BMI increase (+0.19 kg/m2).
Although the intervention appeared to produce a signifi-
cant change (−1.0 kg/m2) in our pilot study, the full study's 
8-month intervention effect was not superior to that of the 
single educational session, that is, sample size was too small 
to detect any change with a power of 80%. We can suggest 
3 explanations for the difference in treatment effect between 
the pilot and in the full study: Firstly, post hoc analysis 
revealed an uneven distribution of normal weight patients 
between the pilot's IG (5 of 9 patients, 56%) and CG (3 of 8 
patients, 38%). In contrast, the full study's distribution was 
even across the 2 groups. As initial BMI may be a risk for 
weight gain,30,31 for example, due to long-term dietary hab-
its, the pilot CG's higher percentage of patients with over-
weight or obesity, and possibly a higher risk for weight gain 
may have increased the difference between it and the IG. 
Secondly, fidelity to the intervention was not fully provided: 
8.1 % of the CG received a second intervention, mainly to 
ensure safe self-management, and 12.5% of the IG had <7 
intervention sessions, mainly due to re-hospitalizations. The 
provision of more care to the CG and omission of interven-
tions in the IG may have masked noteworthy CG-IG differ-
ences. Thirdly, statistical outliers were excluded in the pilot 
due to its small sample size, but were included in the final 
study. This difference in statistical methodology may have 
contributed to an overestimation of the pilot study's treat-
ment effect.
In sum, both the IG and the CG demonstrated good weight 
management. Several factors might explain why weight gain 
was a less serious issue than initially expected.
Firstly, our study cohorts' success in weight management 
may reflect their high mean physical activity level. Both 
groups were walking over 10 000 steps per day at month 8, 
with around two-thirds of those steps performed at medium 
to high intensity. Still, cardiovascular minutes were lower than 
the recommended 150 per week. These were probably under-
reported because we counted only step-based activity and 
steps with high cadence. Thus, walking uphill may be at lower 
cadence, but still be intense for patients.
Second, our results may reflect a Hawthorne effect, that 
is, the tendency of test subjects to behave differently when 
under observation, or a selection bias, including more patients 
who were motivated toward weight control. In this study, NPs 
with BMIs ≥18.5 who received the control intervention had a 
mean increase in BMI from baseline to month 12 of 0.34 kg/
m2, which is slightly higher than observed in either the CG or 
the IG.
Third, our selection criteria may have resulted in a sam-
ple less prone to weight gain than the overall Swiss cohort. 
Reselecting according to that cohort's sample criteria and 
including only first kidney recipients, the mean BMI of our 
95 (of 123) participants and our 65 (of 87) NPs was 25.29 
at baseline and 25.66 at month 12, resulting in a mean BMI 
change of +0.37 kg/m2 over the year. The Swiss cohort's mean 
Baseline BMI was 25.8 and 26.4 at month 12, resulting in an 
average weight gain of +0.6 kg/m2.2 Unlike the Swiss cohort, 
we excluded non-German- or Italian-speaking patients, sug-
gesting that patients with immigration backgrounds are 
particularly prone to first year posttransplant weight gain. 
Further research is needed in this regard.
LTI increased slightly from baseline to month 8 and 
decreased slightly between months 8 and 12. The values of 
this population are within the reference values—approxi-
mately 12–16 LTI (kg /m2) for woman and approximately 
15–20 LTI (kg /m2) for men 50 years of age32 here. According 
to the WHO, the risk of metabolic complications is increased 
by a waist-hip ratio of ≥0.85 for women and ≥0.90 for 
men.33 Although our sample's waist-to-hip-ration decreased 
over the 12 months, the means were higher for both groups 
at all measurement points. A main factor for the higher ratio 
may be steroid use, which leads to fat redistribution to the 
abdomen.
Strengths and Limitations of the Study and 
Intervention
This complex intervention's main strength is the high level 
of patient involvement throughout the entire study period. 
This led to high patient acceptability, which was reflected in 
low drop-out rates. As a weakness, our sample size calculation 
was based on a much higher weight gain effect (BMI change of 
1 kg/m2). In the final study, then, the effect was much smaller, 
leading to a lack of statistical power.
Recommendation for Practice and Future Research
Both interventions (usual care and IG) helped patients with 
normal weight to maintain weight and patients with over-
weight and obesity to lose weight in the first year after trans-
plantation. This indicates that BMI category (underweight, 
normal, overweight, obesity) at time of transplantation may 
be a useful criterion for stratifying the dose (one versus sev-
eral) and manner (educational versus behavioral) of interven-
tion. However, other risk factors for weight gain may also be 
relevant. Further research is needed to explore which patients 
benefit from more complex interventions.
CONCLUSIONS
This behavioral weight and activity intervention had excel-
lent acceptability and supported patients in controlling weight 
gain, but showed no statistical significant advantage over a 
single educational session. To recommend stratified interven-
tions based on patients' risk profiles, further research will need 
to focus on risk factors for weight gain in all BMI categories.
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.  9Schmid-Mohler et al
ACKNOWLEDGMENTS
We thank Nathalie Bodri, Sina Peyer, and Elisabeth 
Samland for data collection. We thank Chris Shultis for edit-
ing support. We thank Regula Lässer and Sandra Bollhalder, 
nutritionists, for the valuable collaboration in developing 
the nutritional intervention and their ongoing support in 
nutritional questions during the study. We thank Professor 
Dr. Stephan Segerer for his assistance regarding the Body 
Impedance Analysis. Our sincere gratitude to Beatrice Biotti, 
Head Nurse, Department Abdomen-Metabolism, for her ini-
tiative to foster this project and her ongoing support.
REFERENCES
 1. Kasiske BL, Zeier MG, Chapman JR, et al; Kidney Disease: Improving 
Global Outcomes. KDIGO clinical practice guideline for the care of kid-
ney transplant recipients: a summary. Kidney Int. 2010;77:299–311.
 2. Beckmann S, Nikolic N, Denhaerynck K, et al. Evolution of body 
weight parameters up to 3 years after solid organ transplantation: 
the prospective Swiss Transplant Cohort Study. Clin Transplant. 
2017;31:1–11.
 3. Zelle DM, Kok T, Dontje ML, et al. The role of diet and physical activ-
ity in post-transplant weight gain after renal transplantation. Clin 
Transplant. 2013;27:E484–E490.
 4. Lafranca JA, IJermans JN, Betjes MG, et al. Body mass index and 
outcome in renal transplant recipients: a systematic review and meta-
analysis. BMC Med. 2015;13:111.
 5. Bundesamt für Gesundheit, Bundesamt für Statistik. Schweizerische 
Gesundheitsbefragung 2012: Übergewicht und Adipositas. Federal 
Office of Public Health (FOPH). Neuchatel, Switzerland;2014.
 6. Ahmadi SF, Zahmatkesh G, Streja E, et al. Body mass index and mor-
tality in kidney transplant recipients: a systematic review and meta-
analysis. Am J Nephrol. 2014;40:315–324.
 7. Sood A, Hakim DN, Hakim NS. Consequences of recipient obesity on 
postoperative outcomes in a renal transplant: a systematic review and 
meta-analysis. Exp Clin Transplant. 2016;14:121–128.
 8. Hill CJ, Courtney AE, Cardwell CR, et al. Recipient obesity and out-
comes after kidney transplantation: a systematic review and meta-
analysis. Nephrol Dial Transplant. 2015;30:1403–1411.
 9. Nicoletto BB, Fonseca NK, Manfro RC, et al. Effects of obesity on kid-
ney transplantation outcomes: a systematic review and meta-analysis. 
Transplantation. 2014;98:167–176.
 10. Chang SH, McDonald SP. Post-kidney transplant weight 
change as marker of poor survival outcomes. Transplantation. 
2008;85:1443–1448.
 11. Kim Y, Kim JR, Choi H, et al. Patients with persistent new-onset dia-
betes after transplantation have greater weight gain after kidney trans-
plantation. J Korean Med Sci. 2013;28:1431–1434.
 12. Ducloux D, Kazory A, Simula-Faivre D, et al. One-year post-trans-
plant weight gain is a risk factor for graft loss. Am J Transplant. 
2005;5:2922–2928.
 13. Orazio LK, Murray EM, Campbell KL. Guideline use: a survey of 
dietitians working with adult kidney transplant recipients. Nephrology 
(Carlton). 2012;17:508–513.
 14. Guida B, Trio R, Laccetti R, et al. Role of dietary intervention on meta-
bolic abnormalities and nutritional status after renal transplantation. 
Nephrol Dial Transplant. 2007;22:3304–3310.
 15. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant 
Work Group. KDIGO clinical practice guideline for the care of 
kidney transplant recipients. Am J Transplant. 2009;9 Suppl 
3:S1–155.
 16. Transplantationszentrum Universitätsspital Zürich. Wissenswertes für 
das Leben nach einer Nierentransplantation: Broschüre 3 (German 
version). In: Klinik für Nephrologie Universitätsspital Zürich. Zürich: 
Transpantationszentrum Universitätsspital Zürich; 2011:1–76.
 17. Centro Trapianti Clinica Universitaria di Zurigo. Informazioni neces-
sarie per la vita dopo und trapianto di rene: Brochure 3 (Italian ver-
sion). In: Clinica di nefrologia Clinica Universitaria di Zurigo. Zurigo: 
2011:1–76.
 18. Brouwers MC, Kerkvliet K, Spithoff K; AGREE Next Steps Consortium. 
The AGREE reporting checklist: a tool to improve reporting of clinical 
practice guidelines. BMJ. 2016;352:i1152.
 19. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for 
Change. New York, NY: The Guilford Press; 2002.
 20. Lundahl B, Moleni T, Burke BL, et al. Motivational interview-
ing in medical care settings: a systematic review and meta-
analysis of randomized controlled trials. Patient Educ Couns. 
2013;93:157–168.
 21. World Health Organization. Obesity: preventing and managing 
the global epidemic – report of a WHO consultation. World Health 
Organisation Technical Report Series 2008:1–253.
 22. IPAQ group. IPAQ: International Physical Activity Questionnaire. 
Available at https://sites.google.com/site/theipaq/questionnaire_links. 
Published 2019. Accessed July 31, 2019.
 23. Craig CL, Marshall AL, Sjöström M, et al. International physical activity 
questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 
2003;35:1381–1395.
 24. Hallal PC, Gomez LF, Parra DC, et al. Lessons learned after 10 years 
of IPAQ use in Brazil and Colombia. J Phys Act Health. 2010;7 Suppl 
2:S259–S264.
 25. Tudor-Locke C, Han H, Aguiar EJ, et al. How fast is fast enough? 
Walking cadence (steps/min) as a practical estimate of intensity in 
adults: a narrative review. Br J Sports Med. 2018;52:776–788.
 26. Epping-Jordan JE, Pruitt SD, Bengoa R, et al. Improving the qual-
ity of health care for chronic conditions. Qual Saf Health Care. 
2004;13:299-305.
 27. Glasgow RE, Wagner EH, Schaefer J, et al. Development and valida-
tion of the patient assessment of chronic illness care (PACIC). Med 
Care. 2005;43:436–444.
 28. Whitlock EP, Orleans CT, Pender N, et al. Evaluating primary care 
behavioral counseling interventions: an evidence-based approach. 
Am J Prev Med. 2002;22:267–284.
 29. Rosemann T, Laux G, Droesemeyer S, et al. Evaluation of a culturally 
adapted German version of the Patient Assessment of Chronic Illness 
Care (PACIC 5A) questionnaire in a sample of osteoarthritis patients. J 
Eval Clin Pract. 2007;13:806–813.
 30. Chan W, Bosch JA, Jones D, et al. Obesity in kidney transplantation. 
J Ren Nutr. 2014;24:1–12.
 31. Ersoy A, Baran B, Ersoy C, et al. Calcineurin inhibitors and post-trans-
plant weight gain. Nephrology (Carlton). 2008;13:433–439.
 32. Fresenius Medical Care Germany. Body Composition Monitor: 
Reference Range. Available at http://www.bcm-fresenius.de/cps/rde/
xchg/SID-C735597B-CAAE68AE/fme-bcm/hs.xsl/23.htm. Accessed 
September 26, 2018.
 33. World Health Organization. Waist circumference and waist-hip ratio: 
Report of a WHO expert consultation: Geneva, 8-11 December 2008. 
Geneva, Switzerland: World Health Organization;2011.
